260 related articles for article (PubMed ID: 33983905)
21. Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.
Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
Mol Cancer Res; 2023 Jun; 21(6):535-547. PubMed ID: 36920288
[TBL] [Abstract][Full Text] [Related]
22. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
23. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
[TBL] [Abstract][Full Text] [Related]
24. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.
Allander SV; Illei PB; Chen Y; Antonescu CR; Bittner M; Ladanyi M; Meltzer PS
Am J Pathol; 2002 Nov; 161(5):1587-95. PubMed ID: 12414507
[TBL] [Abstract][Full Text] [Related]
25. The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.
Banito A; Li X; Laporte AN; Roe JS; Sanchez-Vega F; Huang CH; Dancsok AR; Hatzi K; Chen CC; Tschaharganeh DF; Chandwani R; Tasdemir N; Jones KB; Capecchi MR; Vakoc CR; Schultz N; Ladanyi M; Nielsen TO; Lowe SW
Cancer Cell; 2018 Mar; 33(3):527-541.e8. PubMed ID: 29502955
[TBL] [Abstract][Full Text] [Related]
26. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability.
Benabdallah NS; Dalal V; Scott RW; Marcous F; Sotiriou A; Kommoss FKF; Pejkovska A; Gaspar L; Wagner L; Sánchez-Rivera FJ; Ta M; Thornton S; Nielsen TO; Underhill TM; Banito A
Nat Struct Mol Biol; 2023 Nov; 30(11):1640-1652. PubMed ID: 37735617
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
28. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.
Euhus D; Bu D; Xie XJ; Sarode V; Ashfaq R; Hunt K; Xia W; O'Shaughnessy J; Grant M; Arun B; Dooley W; Miller A; Flockhart D; Lewis C
Cancer Prev Res (Phila); 2011 Nov; 4(11):1852-62. PubMed ID: 21778330
[TBL] [Abstract][Full Text] [Related]
30. Stem cell transcription factor SOX2 in synovial sarcoma and other soft tissue tumors.
Zayed H; Petersen I
Pathol Res Pract; 2018 Jul; 214(7):1000-1007. PubMed ID: 29773426
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
32. SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas.
Jones KB; Su L; Jin H; Lenz C; Randall RL; Underhill TM; Nielsen TO; Sharma S; Capecchi MR
Oncogene; 2013 May; 32(18):2365-71, 2375.e1-5. PubMed ID: 22797074
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo.
Takenaka S; Naka N; Araki N; Hashimoto N; Ueda T; Yoshioka K; Yoshikawa H; Itoh K
Int J Oncol; 2010 Apr; 36(4):823-31. PubMed ID: 20198325
[TBL] [Abstract][Full Text] [Related]
34. Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.
Peng C; Zhao H; Chen W; Song Y; Wang X; Li J; Qiao Y; Wu D; Ma S; Wang X; Gao C
Oncotarget; 2016 Oct; 7(41):66822-66834. PubMed ID: 27572315
[TBL] [Abstract][Full Text] [Related]
35. The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4.
de Bruijn DR; van Dijk AH; Willemse MP; van Kessel AG
Oncogene; 2008 Jan; 27(5):653-62. PubMed ID: 17667940
[TBL] [Abstract][Full Text] [Related]
36. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
[TBL] [Abstract][Full Text] [Related]
37. Expression of claudin7 is tightly associated with epithelial structures in synovial sarcomas and regulated by an Ets family transcription factor, ELF3.
Kohno Y; Okamoto T; Ishibe T; Nagayama S; Shima Y; Nishijo K; Shibata KR; Fukiage K; Otsuka S; Uejima D; Araki N; Naka N; Nakashima Y; Aoyama T; Nakayama T; Nakamura T; Toguchida J
J Biol Chem; 2006 Dec; 281(50):38941-50. PubMed ID: 17060315
[TBL] [Abstract][Full Text] [Related]
38. Neuronal differentiation of synovial sarcoma and its therapeutic application.
Ishibe T; Nakayama T; Aoyama T; Nakamura T; Toguchida J
Clin Orthop Relat Res; 2008 Sep; 466(9):2147-55. PubMed ID: 18563503
[TBL] [Abstract][Full Text] [Related]
39. E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma.
Saito T; Oda Y; Kawaguchi K; Sugimachi K; Yamamoto H; Tateishi N; Tanaka K; Matsuda S; Iwamoto Y; Ladanyi M; Tsuneyoshi M
Oncogene; 2004 Nov; 23(53):8629-38. PubMed ID: 15467754
[TBL] [Abstract][Full Text] [Related]
40. FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance.
Li Y; Qiu X; Wang X; Liu H; Geck RC; Tewari AK; Xiao T; Font-Tello A; Lim K; Jones KL; Morrow M; Vadhi R; Kao PL; Jaber A; Yerrum S; Xie Y; Chow KH; Cejas P; Nguyen QD; Long HW; Liu XS; Toker A; Brown M
Nat Cell Biol; 2021 Nov; 23(11):1187-1198. PubMed ID: 34737445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
